secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001213900-25-032468
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC FY2024 revenue $509.6K (+234%), net loss narrows 77% to $4.9M, EPS $(0.42)
-------------------------------------------------------------------------------

- Revenue surged 234% to $509,589 driven by licensing milestones.
- Net loss improved to $4.90M from $7.79M; EPS improved 77% to $(0.42).
- Operating expenses reduced 21% to $5.21M, R&D down 83%, SG&A down 58%.
- Stock-based compensation increased to $2.77M from $0.19M to preserve cash.
- Remaining milestone potential of up to $18.3M under existing licensing deals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025032468/0001213900-25-032468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025032468/ea0238544-8ka1_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-032468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer